Matthew T. Plano - May 26, 2022 Form 4 Insider Report for ABIOMED INC (NASD)

Role
VP, GLOBAL OPERATIONS
Signature
/s/ Marc A. Began (by power of attorney)
Stock symbol
NASD
Transactions as of
May 26, 2022
Transactions value $
-$232,515
Form type
4
Date filed
6/1/2022, 06:28 PM
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock $.01 par value Award $0 +2.45K +25.42% $0.00 12.1K May 26, 2022 Direct F1
transaction NASD Common Stock $.01 par value Award $0 +1.5K +12.4% $0.00 13.6K May 29, 2022 Direct F2
transaction NASD Common Stock $.01 par value Tax liability -$177K -666 -4.9% $266.34* 12.9K May 29, 2022 Direct F3
transaction NASD Common Stock $.01 par value Tax liability -$55.1K -207 -1.6% $266.34* 12.7K May 29, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (Right to Buy) 2K May 26, 2022 Common Stock 0 $381.97 Direct F4, F5
holding NASD Stock Option (Right to Buy) 5K May 26, 2022 Common Stock 0 $266.39 Direct F4, F5
holding NASD Stock Option (Right to Buy) 2.77K May 26, 2022 Common Stock 0 $223.90 Direct F4, F5
holding NASD Stock Option (Right to Buy) 2.77K May 26, 2022 Common Stock 0 $283.88 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates.
F2 Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone.
F3 Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards.
F4 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F5 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2